Chimeric antigen receptor (CAR)-T cell therapies have revolutionised treatment for hematological cancers; however, current ex vivo CAR-T cell therapies face logistical, manufacturing and clinical integration challenges. Emerging fast-manufacturing platforms offer promising clinical outcomes with reduced turnaround times, improved efficacay and safety, and potential for first-line treatment use.
This program aims to provide hematologists and oncologists with the latest data and discussion-based insights on emerging CAR-T cell therapies for high-risk LBCL and R/R DLBCL that aim to reduce the time of CAR-T cell therapy delivery, generating confidence for timely integration into clinical practice on approval.
Latest content
Latest content
Learning objectives
- Describe the challenges of traditional CAR-T cell therapies in hematological cancers such as LBCL and R/R DLBCL including time to treatment initiation, the need for bridging therapies and adverse event profiles
- Differentiate between traditional CAR-T cell therapy platforms and emerging platforms used for hematological cancers such as high-risk LBCL and R/R DLBCL based on differences in process, total turnaround time, T cell quality assurance and cost
- Recall the clinical trial evidence for CAR-T cell therapies in development for high-risk LBCL and R/R DLBCL delivered using novel delivery platforms in hematological cancers and the value of reducing time to CAR-T cell therapy initiation in high-risk patients
Learning objectives
- Describe the challenges of traditional CAR-T cell therapies in hematological cancers such as LBCL and R/R DLBCL including time to treatment initiation, the need for bridging therapies and adverse event profiles
- Differentiate between traditional CAR-T cell therapy platforms and emerging platforms used for hematological cancers such as high-risk LBCL and R/R DLBCL based on differences in process, total turnaround time, T cell quality assurance and cost
- Recall the clinical trial evidence for CAR-T cell therapies in development for high-risk LBCL and R/R DLBCL delivered using novel delivery platforms in hematological cancers and the value of reducing time to CAR-T cell therapy initiation in high-risk patients
Target audience
This program is aimed at specialist and community hematologists, oncologists and the wider healthcare team involved in treating patients with CAR-T therapies. This activity is for healthcare professionals outside of the USA and UK.
Planning committee
In addition to the expert faculty, Springer Health+ IME planners and staff include Rachel Goddard and Lucy Piper. The planning committee have no financial relationships to disclose.
All relevant financial relationships of the faculty have been mitigated.
